229 related articles for article (PubMed ID: 32852902)
1. Optimizing skeletal-related events prevention in patients with advanced prostate cancer.
Leung AK
Asia Pac J Clin Oncol; 2020 Sep; 16 Suppl 3():4-6. PubMed ID: 32852902
[TBL] [Abstract][Full Text] [Related]
2. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
[TBL] [Abstract][Full Text] [Related]
3. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.
Smith MR; Coleman RE; Klotz L; Pittman K; Milecki P; Ng S; Chi KN; Balakumaran A; Wei R; Wang H; Braun A; Fizazi K
Ann Oncol; 2015 Feb; 26(2):368-74. PubMed ID: 25425475
[TBL] [Abstract][Full Text] [Related]
4. Revisiting the role of bone-modifying agents in the management of metastatic prostate cancer.
Cheung FY
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():13-15. PubMed ID: 30489032
[TBL] [Abstract][Full Text] [Related]
5. Managing bone metastases and reducing skeletal related events in prostate cancer.
Gartrell BA; Saad F
Nat Rev Clin Oncol; 2014 Jun; 11(6):335-45. PubMed ID: 24821212
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
7. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
[TBL] [Abstract][Full Text] [Related]
8. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.
Snedecor SJ; Carter JA; Kaura S; Botteman MF
J Med Econ; 2013; 16(1):19-29. PubMed ID: 22870908
[TBL] [Abstract][Full Text] [Related]
9. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
[TBL] [Abstract][Full Text] [Related]
10. Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
Graff JN; Beer TM
Oncology (Williston Park); 2015 Jun; 29(6):416-23. PubMed ID: 26091674
[TBL] [Abstract][Full Text] [Related]
11. Pathologic fracture in patients with metastatic prostate cancer.
Gartrell BA; Saad F
Curr Opin Urol; 2014 Nov; 24(6):595-600. PubMed ID: 25166424
[TBL] [Abstract][Full Text] [Related]
12. Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer?
Saylor PJ; Michaelson MD
Oncologist; 2012; 17(2):288-90. PubMed ID: 22267850
[TBL] [Abstract][Full Text] [Related]
13. Targeting bone metastases in prostate cancer: improving clinical outcome.
Body JJ; Casimiro S; Costa L
Nat Rev Urol; 2015 Jun; 12(6):340-56. PubMed ID: 26119830
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
15. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.
Klaassen Z; Howard LE; de Hoedt A; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Cancer; 2017 May; 123(9):1528-1535. PubMed ID: 28026865
[TBL] [Abstract][Full Text] [Related]
16. Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer.
El-Amm J; Aragon-Ching JB
Clin Med Insights Oncol; 2016; 10(Suppl 1):11-9. PubMed ID: 27042152
[TBL] [Abstract][Full Text] [Related]
17. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.
Dorff TB; Agarwal N
Asian J Androl; 2018; 20(3):215-220. PubMed ID: 29553053
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
Cristino J; Finek J; Jandova P; Kolek M; Pásztor B; Giannopoulou C; Qian Y; Brezina T; Lothgren M
J Med Econ; 2017 Aug; 20(8):799-812. PubMed ID: 28485692
[TBL] [Abstract][Full Text] [Related]
19. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Tablazon IL; Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ; Williams SB
Cancer; 2019 Nov; 125(22):4003-4010. PubMed ID: 31390061
[TBL] [Abstract][Full Text] [Related]
20. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer.
Saad F
Clin Prostate Cancer; 2005 Jun; 4(1):31-7. PubMed ID: 15992459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]